Vanguard Capital Management’s Standard BioTools LAB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$9.26M Buy
12,496,998
+244,000
+2% +$187K ﹤0.01% 2809
2026
Q2
$10.1M Sell
12,252,998
-563,072
-4% -$532K ﹤0.01% 2809
2026
Q1
$11.8M Buy
+12,816,070
New +$15.5M ﹤0.01% 2638

Other funds holding LAB

Vanguard Capital Management's LAB Position: Q3 2026 in Review

Vanguard Capital Management increased its Standard BioTools (LAB) stake by 2% in Q3 2026, buying an estimated $187K and bringing the position to 12,496,998 shares worth $9.26M. The position accounts for ﹤0.01% of the portfolio, ranked #2809.

Vanguard Capital Management first reported a position in LAB in Q1 2026 and has held it in 3 quarters since. The position peaked at $11.8M in Q1 2026. 104 funds tracked by Wall St. Rank hold LAB as of Q3 2026.

  • Vanguard Capital Management held 12,496,998 shares of Standard BioTools worth $9.26M as of Q3 2026.
  • Vanguard Capital Management bought 244,000 Standard BioTools shares in Q3 2026, an estimated $187K.
  • Standard BioTools made up ﹤0.01% of Vanguard Capital Management's portfolio in Q3 2026, its #2809 holding.
  • Vanguard Capital Management first reported a position in Standard BioTools in Q1 2026 and has held it in 3 quarters since.
  • Vanguard Capital Management's Standard BioTools position peaked at $11.8M in Q1 2026.
  • 104 funds tracked by Wall St. Rank held Standard BioTools as of Q3 2026.

Based on Vanguard Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.